Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiotherapy Planning, Computer-Assisted | 16 | 2021 | 51 | 2.500 |
Why?
|
| Radiotherapy Dosage | 17 | 2021 | 96 | 1.410 |
Why?
|
| Brachytherapy | 7 | 2021 | 39 | 1.390 |
Why?
|
| Radiotherapy, Intensity-Modulated | 7 | 2020 | 36 | 1.280 |
Why?
|
| Brain Neoplasms | 6 | 2013 | 77 | 1.070 |
Why?
|
| Hippocampus | 5 | 2013 | 260 | 1.060 |
Why?
|
| Head and Neck Neoplasms | 3 | 2017 | 143 | 1.030 |
Why?
|
| Radiometry | 8 | 2017 | 24 | 0.980 |
Why?
|
| Cranial Irradiation | 4 | 2011 | 10 | 0.890 |
Why?
|
| Radiation Injuries | 4 | 2011 | 28 | 0.870 |
Why?
|
| Radiotherapy, Conformal | 5 | 2017 | 18 | 0.810 |
Why?
|
| Glioma | 2 | 2013 | 18 | 0.790 |
Why?
|
| Pluripotent Stem Cells | 2 | 2011 | 6 | 0.720 |
Why?
|
| Employment | 1 | 2021 | 37 | 0.710 |
Why?
|
| Organs at Risk | 3 | 2017 | 7 | 0.700 |
Why?
|
| Radiosurgery | 3 | 2020 | 34 | 0.690 |
Why?
|
| Parotid Gland | 2 | 2017 | 17 | 0.680 |
Why?
|
| Organ Sparing Treatments | 2 | 2017 | 12 | 0.680 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2017 | 171 | 0.630 |
Why?
|
| Internship and Residency | 1 | 2021 | 171 | 0.590 |
Why?
|
| Xerostomia | 1 | 2017 | 6 | 0.580 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 110 | 0.560 |
Why?
|
| Phantoms, Imaging | 5 | 2020 | 33 | 0.520 |
Why?
|
| Monte Carlo Method | 5 | 2018 | 50 | 0.480 |
Why?
|
| Gamma Rays | 1 | 2015 | 14 | 0.470 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 28 | 0.470 |
Why?
|
| Limbic System | 2 | 2011 | 7 | 0.460 |
Why?
|
| Tomography, Spiral Computed | 2 | 2011 | 24 | 0.430 |
Why?
|
| Neural Stem Cells | 1 | 2013 | 12 | 0.420 |
Why?
|
| Scattering, Radiation | 4 | 2020 | 33 | 0.410 |
Why?
|
| Humans | 31 | 2021 | 25165 | 0.370 |
Why?
|
| Breast Neoplasms | 6 | 2017 | 379 | 0.370 |
Why?
|
| Lung Neoplasms | 5 | 2020 | 544 | 0.340 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2015 | 30 | 0.320 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2018 | 637 | 0.310 |
Why?
|
| Electrons | 2 | 2009 | 19 | 0.310 |
Why?
|
| Computer Simulation | 4 | 2018 | 186 | 0.290 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2018 | 8 | 0.270 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 641 | 0.260 |
Why?
|
| Algorithms | 4 | 2018 | 338 | 0.250 |
Why?
|
| Rectum | 2 | 2021 | 50 | 0.220 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 450 | 0.210 |
Why?
|
| Feasibility Studies | 4 | 2011 | 208 | 0.210 |
Why?
|
| Models, Biological | 1 | 2004 | 313 | 0.190 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 8 | 0.190 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2021 | 4 | 0.190 |
Why?
|
| Body Burden | 3 | 2013 | 7 | 0.190 |
Why?
|
| Vagina | 1 | 2021 | 29 | 0.190 |
Why?
|
| Physics | 1 | 2021 | 4 | 0.180 |
Why?
|
| Female | 14 | 2021 | 14161 | 0.180 |
Why?
|
| Sarcoma | 1 | 2021 | 65 | 0.180 |
Why?
|
| Molecular Imaging | 1 | 2020 | 4 | 0.180 |
Why?
|
| Male | 10 | 2018 | 13815 | 0.160 |
Why?
|
| Proton Therapy | 1 | 2018 | 2 | 0.150 |
Why?
|
| Photons | 1 | 2018 | 4 | 0.150 |
Why?
|
| Acoustics | 1 | 2018 | 19 | 0.150 |
Why?
|
| Prognosis | 2 | 2017 | 693 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 172 | 0.140 |
Why?
|
| Relative Biological Effectiveness | 2 | 2010 | 5 | 0.140 |
Why?
|
| Intraoperative Care | 1 | 2017 | 41 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 1032 | 0.140 |
Why?
|
| Particle Accelerators | 2 | 2009 | 5 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 90 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2017 | 46 | 0.130 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 86 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2014 | 240 | 0.130 |
Why?
|
| Radiation Dosage | 1 | 2015 | 38 | 0.120 |
Why?
|
| Intestine, Small | 1 | 2015 | 29 | 0.120 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2006 | 20 | 0.120 |
Why?
|
| United States | 1 | 2021 | 1928 | 0.120 |
Why?
|
| Equipment Design | 2 | 2012 | 132 | 0.120 |
Why?
|
| Whole-Body Irradiation | 2 | 2012 | 9 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 57 | 0.110 |
Why?
|
| Quality of Life | 1 | 2017 | 594 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 177 | 0.100 |
Why?
|
| Medical Illustration | 1 | 2012 | 12 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2012 | 13 | 0.100 |
Why?
|
| Equipment Failure Analysis | 1 | 2012 | 94 | 0.090 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2011 | 2 | 0.090 |
Why?
|
| Prone Position | 1 | 2011 | 31 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 88 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2011 | 70 | 0.090 |
Why?
|
| Pituitary Gland | 1 | 2010 | 13 | 0.090 |
Why?
|
| Lateral Ventricles | 1 | 2010 | 5 | 0.090 |
Why?
|
| Dentate Gyrus | 1 | 2010 | 6 | 0.090 |
Why?
|
| Brain Stem | 1 | 2010 | 18 | 0.090 |
Why?
|
| Computer-Aided Design | 1 | 2009 | 10 | 0.080 |
Why?
|
| Larynx | 1 | 2009 | 10 | 0.080 |
Why?
|
| Heart | 1 | 2009 | 59 | 0.080 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2009 | 20 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2009 | 28 | 0.080 |
Why?
|
| Carcinoma | 1 | 2009 | 66 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2021 | 3185 | 0.070 |
Why?
|
| Axilla | 1 | 2008 | 13 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 31 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2013 | 3204 | 0.070 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 17 | 0.070 |
Why?
|
| Skin Transplantation | 1 | 2006 | 12 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 15 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2006 | 59 | 0.060 |
Why?
|
| Adult | 3 | 2013 | 7259 | 0.060 |
Why?
|
| Histocompatibility | 1 | 2004 | 3 | 0.060 |
Why?
|
| Transplantation Conditioning | 1 | 2004 | 24 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2004 | 125 | 0.050 |
Why?
|
| Survival Rate | 2 | 2014 | 290 | 0.050 |
Why?
|
| Aged | 5 | 2014 | 8448 | 0.050 |
Why?
|
| Cognition | 1 | 2010 | 1270 | 0.050 |
Why?
|
| Middle Aged | 5 | 2014 | 8303 | 0.050 |
Why?
|
| Brain | 1 | 2010 | 1543 | 0.050 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2018 | 4 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 29 | 0.040 |
Why?
|
| Water | 1 | 2017 | 30 | 0.040 |
Why?
|
| Carcinoma, Large Cell | 1 | 2014 | 12 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2013 | 17 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 40 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 273 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 134 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 331 | 0.030 |
Why?
|
| Celiac Artery | 1 | 2012 | 1 | 0.020 |
Why?
|
| Pancreaticojejunostomy | 1 | 2012 | 1 | 0.020 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2012 | 2 | 0.020 |
Why?
|
| Anatomic Landmarks | 1 | 2012 | 4 | 0.020 |
Why?
|
| Aortography | 1 | 2012 | 6 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2012 | 4 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 23 | 0.020 |
Why?
|
| Consensus | 1 | 2012 | 83 | 0.020 |
Why?
|
| Portal Vein | 1 | 2012 | 38 | 0.020 |
Why?
|
| Supine Position | 1 | 2011 | 20 | 0.020 |
Why?
|
| X-Ray Film | 1 | 2011 | 2 | 0.020 |
Why?
|
| Artifacts | 1 | 2011 | 29 | 0.020 |
Why?
|
| Software | 1 | 2011 | 58 | 0.020 |
Why?
|
| Lung | 1 | 2011 | 163 | 0.020 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2010 | 7 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2011 | 174 | 0.020 |
Why?
|
| Metals | 1 | 2011 | 135 | 0.020 |
Why?
|
| Calibration | 1 | 2009 | 19 | 0.020 |
Why?
|
| Radiation Protection | 1 | 2009 | 4 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2009 | 25 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2009 | 81 | 0.020 |
Why?
|
| Models, Anatomic | 1 | 2009 | 36 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 1672 | 0.020 |
Why?
|
| Iridium Radioisotopes | 1 | 2008 | 3 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2008 | 29 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 566 | 0.020 |
Why?
|
| Animals | 2 | 2006 | 3430 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 140 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 704 | 0.020 |
Why?
|
| Rats, Inbred ACI | 1 | 2006 | 1 | 0.020 |
Why?
|
| Chimerism | 1 | 2006 | 4 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 37 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 387 | 0.010 |
Why?
|
| Rats | 1 | 2006 | 639 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2004 | 1 | 0.010 |
Why?
|
| Hemibody Irradiation | 1 | 2004 | 2 | 0.010 |
Why?
|
| Papio | 1 | 2004 | 4 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2004 | 14 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2004 | 16 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 26 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2004 | 20 | 0.010 |
Why?
|
| Injections | 1 | 2004 | 39 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2004 | 33 | 0.010 |
Why?
|
| Graft Survival | 1 | 2004 | 81 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2004 | 237 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 1300 | 0.010 |
Why?
|